Quick Answer
NovaBridge Biosciences reported Diluted EPS of $0.12 per share (loss) for fiscal year 2024.
NovaBridge Biosciences Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2024 | -$0.12 | +89.0% |
| 2023 | -$1.09 | +44.4% |
| 2022 | -$1.96 | +85.3% |
| 2021 | -$13.35 | -545.0% |
| 2020 | $3.00 | +101.5% |
| 2019 | -$201.19 | -226.1% |
| 2018 | -$61.70 | -18.8% |
| 2017 | -$51.93 | — |
- NovaBridge Biosciences showed an increase of +89.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2017–2024 period, NovaBridge Biosciences’s diluted eps has grown by 99.8% (from $51.93 per share (loss) to $0.12 per share (loss)).
- The most recent figure is from NovaBridge Biosciences’s fiscal year 2024 report (Form 20-F), filed with the SEC on April 3, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: